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Introduction: Metastatic neoplasms to the thyroid gland are rare in clinical practice. Clear cell renal carcinoma is
the most frequent site of origin of thyroid metastases and represents 12 to 34% of all secondary thyroid tumors.
Tumor-to-tumor metastases, in which a thyroid neoplasm is the recipient of a metastasis, are exceedingly rare. We
report a case of clear cell renal carcinoma metastatic to a follicular adenoma. This is the tenth case of renal cell
carcinoma metastasis to thyroid tumor reported in the literature.
Case presentation: A 62-year-old Caucasian woman with a history of clear cell renal carcinoma was admitted to
our institution for multinodular goiter. A histological examination after total thyroidectomy revealed clear cell renal
carcinoma metastasis to a thyroid follicular adenoma.
Conclusions: Preoperative diagnosis of secondary thyroid neoplasm is difficult to achieve. The diagnosis of
metastatic disease should be taken into account if patients have a history of clear cell renal carcinoma or if there is
a multifocal growth pattern and clear cell appearance of the cytoplasm.
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Tumor-to-tumor metastasisIntroduction
Most thyroid gland tumors are primary and include pap-
illary, follicular, medullary and anaplastic carcinomas.
Metastatic thyroid gland tumor is an uncommon finding
in clinical practice. Common sites of primary tumors
that can metastasize to the thyroid gland are lung,
breast, kidney, and head and neck [1]. Tumor-to-tumor
metastases, in which a thyroid neoplasm is the recipient
of a metastasis, are extremely rare [2]; to the best of our
knowledge, only nine cases of renal cell carcinoma me-
tastasis to thyroid tumor have been previously reported
in the literature (Table 1) [3-7].
This report cites a case of metastasis of clear cell renal
carcinoma (CCRC) to a thyroid follicular adenoma.
Case presentation
A 62-year-old Caucasian woman with a 20-year history of
non-toxic multinodular goiter presented to our hospital
for surgical treatment. She had no associated symptoms* Correspondence: pgcalo@unica.it
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reproduction in any medium, provided the orsuch as dysphagia, dyspnea, or dysphonia. Six years earlier,
the patient had undergone a left nephrectomy for clear
cell carcinoma. A physical examination revealed an indo-
lent subhyoid swelling accompanied by a few round nod-
ules. A preoperative neck ultrasound examination showed
an enlarged thyroid gland, with a retrosternal left lobe.
The whole left lobe was occupied by an isoechoic vascu-
larized macronodule. No suspicious central or lateral neck
lymph nodes were found. The indication for surgery was
the result of the sonographic features of the lesion, the
thyroid volume, and the retrosternal position of the left
lobe; for these reasons fine needle aspiration cytology was
considered unnecessary. A total thyroidectomy was per-
formed in our department in April 2010. Her parathyroid
glands and recurrent nerves were recognized and pre-
served. The postoperative course was uneventful, and she
was discharged on the second postoperative day.
Upon macroscopic examination, her thyroid was en-
larged and multinodular. The left lobe, which was larger
than the right one, was occupied by a solid macronodule
measuring 53mm; small yellow areas were observed
within this nodule. A microscopic examination of theLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Renal cell carcinoma metastatic to thyroid neoplasm: characteristics of the cases reported in the literature
Case number Authors Receiving thyroid
neoplasm
Interval Immunohistochemistry
1 Bohn et al. [3] Papillary carcinoma 2 Y THY (−) RCC marker +
2 Rosai et al. cited by Bohn
and Ryska [3,4]
Follicular adenoma NA THY (−)
3 Chacho et al. cited by Ryska [4] Follicular adenoma Synchronous Not done




2 Y THY (−) CK19 (−)
5 Wolf et al. [5] Microfollicular adenoma NA Not done
6 Ryska and Cap [4] Oncocytic carcinoma 13 M THY (−), vimentin (+), calcitonin (−), EMA (+), CK AE1-AE3 (+)
7 Qian et al. [6] Hürthle adenoma Synchronous TTF-1 (−), THY (−), CD10 (+), vimentin (+)
8 Koo et al. cited by Bohn [3] Follicular adenoma 5 Y TTF-1 (−), THY (−), calcitonin (−). Equivocal CK and CD10
9 Yu et al. [7] Papillary carcinoma 3 Y THY (−), TTF-1 (−), CD10 (+), vimentin (+), RCC antigen (−)
10 Medas et al. (present case) Microfollicular adenoma 6 Y TTF-1 (−), THY (−), CD10 (+)
Abbreviations: CK, cytokeratin; EMA, epithelial membrane antigen; M, months; NA, not available; RCC, renal cell carcinoma; THY, thyroglobulin; TTF-1, thyroid
transcription factor-1; Y, years.
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was characterized by microfollicular proliferation with
edema and areas of sclerosis and was surrounded by an in-
complete fibrous capsule. Inside the nodule, small yellow
solid areas were present, and there was a proliferation of
large cells with clear cytoplasm and small and hyperchro-
mic nuclei. This second population of tumor cells was
well-demarcated from the first (Figure 1). Neoplastic cells
were immunonegative for thyroid transcription factor-1
(TTF-1), Hector Battifora mesothelial cell monoclonal
antibody-1, and galectin-3 (Figure 2), whereas CD10 was
positive (Figure 3). Specimens of the previous renal cell
carcinoma were examined, and histopathological featuresFigure 1 Hematoxylin and eosin staining demonstrates two different
clear cytoplasm and small and hyperchromic nuclei. Magnification × 10matched the present histology. With these findings, a
diagnosis of metastasis of renal cell carcinoma in thyroid
follicular adenoma was made.
Postoperative staging demonstrated no other foci of
CCRC metastasis.
Three years after her thyroidectomy, no evidence of
recurrent CCRC has been found.
Discussion
Tumor-to-tumor metastasis can be diagnosed when the
recipient tumor is a true neoplasm and the donor neo-
plasm is a true metastasis [2,8]. Growth of a neoplasm
into an adjacent tumor or the presence of only tumorcomponents: microfollicular proliferation and large cells with
0.
Figure 2 Immunohistochemical stains. Thyroid transcription factor-1 is positive in follicular adenoma and negative in metastatic renal cell
carcinoma. Magnification × 40.
Medas et al. Journal of Medical Case Reports 2013, 7:265 Page 3 of 5
http://www.jmedicalcasereports.com/content/7/1/265emboli within a recipient neoplasm must be excluded.
Our case of CCRC metastasis to a thyroid follicular ad-
enoma meets these criteria.
CCRC represents 3 to 4% of all adult malignancies and is
the third most frequent urologic cancer [9,10]. CCRC con-
stitutes approximately 85% of all primary renal tumors; its
incidence increases with age [9,10]. Nowadays, approxi-
mately 40% of kidney neoplasms are diagnosed incidentally
due to the widespread use of imaging technologies. DataFigure 3 Immunohistochemical stains. CD10 is positive in metastatic renafrom the US Surveillance, Epidemiology, and End Results
study show that 17% of the patients have metastatic disease
at diagnosis. The most frequent sites of metastasis are lung,
bone, liver, adrenal gland, contralateral kidney, retroperito-
neum, brain, and skin; head and neck metastasis are less
frequent, and the thyroid is the site most commonly af-
fected. CCRC recurrence after nephrectomy is highly vari-
able, presenting with metastasis ranging from a few months
to several years after the initial diagnosis [9,10].l cell carcinoma and negative in follicular proliferation. Magnification × 40.
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lignancies; [3] the most common primary tumors are
skin, breast, lung, kidney, and head and neck. The higher
rate of secondary thyroid gland tumors found in autopsy
studies, ranging from 5 to 24% [1], suggests that meta-
static thyroid lesions are often occult. Metastatic thyroid
tumors can represent a first finding of unknown primary
tumor (occult primary neoplasm) or a synchronous or
metachronous manifestation of known primary tumors.
Some authors have suggested that the thyroid is a com-
mon site of metastasis because of its rich blood supply; they
proposed that the thyroid gland would be more susceptible
to metastatic growth when affected by goiter, neoplasms, or
thyroiditis due to metabolic changes that consist of decre-
ments in the oxygen and iodine content [11]. By contrast,
other authors have reported that there is no difference in
frequency of metastasis in altered thyroid glands versus
normal thyroid glands [11].
CCRC metastases to the thyroid gland account for 12 to
34% of all secondary thyroid tumors [1]. Metastatic thyroid
tumors may represent the first manifestation of CCRC or a
synchronous or metachronous metastasis of a known
CCRC. Metastases usually appear as metachronous lesions,
often several years after nephrectomy. As in this case,
metastatic CCRC may first be misinterpreted as a primary
thyroid tumor.
In our case, a secondary thyroid tumor was the first
metastatic site during follow-up for CCRC that had been
diagnosed 6 years earlier.
A tumor-to-tumor metastasis, in which a thyroid neo-
plasm is the recipient tumor, was previously described in
the literature in only 28 cases [2,12], and ours is the 29th;
the most common primary tumor was CCRC with 10 cases
(including our case) [3-6,12], followed by lung carcinoma
(six cases), breast carcinoma (five cases), colon carcinoma
(three cases), and isolated cases of prostate adenocarcin-
oma, melanoma, pancreatic neuroendocrine carcinoma,
Burkitt-like lymphoma, and a malignant phyllodes tumor.
In the 10 cases of CCRC metastasis to thyroid tumor
(including this case), the recipient tumor was follicular
adenoma in five cases [3-5], papillary carcinoma in three
cases [3,12], Hürthle cell adenoma in one case [6], and
Hürthle cell carcinoma in one case [4] (Table 1).
Metastases were metachronous in eight cases [3-5,12]
and synchronous in two cases [3,6] (Table 1). In one case,
the diagnosis was autoptic in a patient with diffuse meta-
static disease [5]. Latency from nephrectomy to diagnosis
of thyroid metastasis varies from 13 months to 6 years. In
the metachronous metastasis group, a thyroid nodule was
found during follow-up for CCRC in seven cases with ultra-
sound examination of the thyroid gland. In one case, patho-
logic uptake of 18F-fluorodeoxyglucose in the thyroid
with 18F-fluorodeoxyglucose-positron emission tomography
was the first finding [5]. In this group, total thyroidectomywas performed in six cases and a loboisthmectomy in one
case; in one case, diagnosis was made post-mortem. In the
synchronous metastasis group, a total thyroidectomy was
performed before nephrectomy for suspicious thyroid
nodule, with pathologic findings suggestive for CCRC
metastasis; further investigations demonstrated a renal
mass, and the patients underwent nephrectomy.
Immunohistochemistry was made in nine cases and
stained positive for the CCRC marker and vimentin and
negative for TTF-1 and thyroglobulin [2-4,6,12].
Although CCRC metastasis to the thyroid gland can be
suspected in patients with a history of renal tumors, pre-
operative diagnosis of primary versus secondary tumor is
difficult. Radiological findings are similar in both cases,
with the nodule being a hypoechoic, non-homogeneous,
and vascularized mass upon ultrasound examination and
“cold” on radioiodine uptake studies. Fine needle aspir-
ation cytology of the lesion can be useful in preoperative
diagnosis, suggesting a secondary neoplasm; nevertheless,
cytological findings are common in primary and second-
ary neoplasms, and a metastatic tumor can be easily mis-
interpreted as a primary tumor [12]. As most authors, we
do not perform a core biopsy when cytological results are
uncertain. Hence, diagnosis of metastatic CCRC is made
with histopathological examination after thyroidectomy.
Clinical history of prior malignancies, multifocal growth
pattern, sinusoidal pattern of vascularization, and clear
cell appearance of the cytoplasm should suggest a second-
ary thyroid tumor to the pathologist [11,12]. Other tumors
with clear cell appearance [11,12], such as paraganglioma
[13], differentiated thyroid cancer (papillary, follicular and
medullary carcinoma), and lung and salivary gland sec-
ondary tumors should be considered in the differential
diagnosis [3,11,12]. Immunohistochemistry can be helpful
for the differential diagnosis, with metastatic cells of
CCRC positive for CD10 and vimentin and negative for
thyroglobulin, calcitonin, and TTF-1 [3]. Nonetheless,
even in a patient with previous CCRC, a new thyroid mass
is more likely to be a primary than a secondary tumor.
Thyroidectomy should be performed in patients with
no other metastases; prognosis is good in this group. By
contrast, patients with disseminated disease have a poor
prognosis and should undergo thyroidectomy only for
palliative care of compressive symptoms. Loboisthmect-
omy may be appropriate if CCRC was preoperatively or
intraoperatively suspected and in the presence of a single
lesion. In our case, even after taking into account the in-
creased risks in case of reoperation, the preoperative
diagnosis of multinodular goiter suggested that total thy-
roidectomy was the most suitable treatment [14,15].
Conclusions
Thyroid metastasis should be considered in patients with a
thyroid nodule and positive history for CCRC. Preoperative
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cult to achieve. Immunohistochemistry is a useful method
for evaluation of patients with suspected nodules, meta-
static cells being negative for thyroglobulin, calcitonin,
TTF-1 and positive for CD10 and vimentin. If the thyroid
gland is the only site of metastasis, a thyroidectomy must
be performed.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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